XJPX
4553
Market cap1.11bUSD
Oct 09, Last price
3,620.00JPY
1D
2.12%
1Q
-10.06%
Jan 2017
137.12%
IPO
352.50%
Name
Towa Pharmaceutical Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Operating in Japan, Towa Pharmaceutical Co., Ltd. and its subsidiaries are engaged in the research, development, production, and sale of prescription drugs, active pharmaceutical ingredients, and intermediates. The company's extensive portfolio addresses critical therapeutic areas such as diabetes, digestive health, neurological conditions, and allergic diseases, alongside offering vitamins, antibiotics, and oncology treatments. With approximately 700 different drug products, Towa Pharmaceutical Co., Ltd. was established in 1951 and is headquartered in Osaka, Japan.
Related entities
Subsidiaries (3)
TOWA PHARMA INTERNATIONAL HOLDINGS S.L. (SOCIEDAD UNIPERSONAL)
TOWA PHARMACEUTICAL EUROPE S.L. (SOCIEDAD UNIPERSONAL)
TOWA PHARMACEUTICAL S.A.
Key people
Itsuro Yoshida
President, Chairman of Subsidiary, Representative Director · since 2024
Shigehiro Kubo
Senior Executive Officer, Chief Director of International Business, Director of Asia Regional Business · since 2023
Yutaka Okuda
Senior Executive Officer, Chief Director of R&D, Senior Director of Fundamental Technology, Director of Innovation Research · since 2024
Tetsuro Tabata
Senior Executive Officer, Chief Director of Production · since 2024
Takahiko Taniguchi
Senior Executive Officer, Chief Director of Active Pharmaceutical Ingredients Business, Director of API, Director of New Materials · since 2025
Shigeki Fujita
Executive Officer, Manager of Human Resource Research Center · since 2024
Shiro Hatagami
Executive Officer, Chief Director of Accounting and Finance · since 2024
Keisuke Hirai
Executive Officer, Senior Director of Product Planning in Main R & D Unit · since 2023
Norikazu Inoue
Executive Officer, Chief Director of Administration · since 2024
Takayuki Kanno
Executive Officer, Manager of Yamagata Plant in Main Production Plant, Director of Engineering · since 2024
Shuichi Katsuki
Executive Officer, Deputy Chief Director of Main Production Unit, Director of Production Technology · since 2022
Katsutoshi Kawamura
Executive Officer, Director of Distribution Planning in Main Sales Unit · since 2016
Mitsuhiro Matsumoto
Executive Officer · since 2022
Jun Matsuo
Executive Officer, Manager of Yamagata Factory in Main Production Unit · since 2023
Masaji Morikawa
Executive Officer, Deputy Chief Director of Main Sales Unit, Director of Hospital Promotion · since 2022
Akira Nishimura
Executive Officer, Senior Director of Pharmaceutical Development in Main R & D Unit, Director of Clinical Analysis · since 2024
Yasuyuki Oishi
Executive Officer, Chief Director of Sales, Manager of Promote Stable Supply · since 2024
Takeshi Sugiura
Executive Officer, Chief Director of Pharmaceutical Business · since 2022
Akifumi Takeuchi
Executive Officer, Osaka Plant Manager in Main Production Unit · since 2025
Toshiyuki Tanaka
Executive Officer, Senior Director of External Affairs · since 2020
Headquarters & legal address
新橋町2番11号
大阪府 門真市 571-8580
JP
大阪府 門真市 571-8580
JP
Address
2-11,Shinbashi-cho
kadoma-shi Osaka 571-8580
JP
kadoma-shi Osaka 571-8580
JP
Other language
Towa Pharmaceutical Co., Ltd.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||